In this multi-site, parallel-group, randomized clinical trial, we will evaluate the efficacy of BRIGHT, a novel psychological intervention for cancer survivors, compared with attention control (AC) for managing body image distress (BID) among head and neck cancer survivors (HNC) survivors, examine BRIGHT’s underlying mechanisms, and characterize factors affecting the future adoption of BRIGHT into clinical care.

1. The researchers will check your medical records to gather information about your diagnosis and treatment. 2. You will meet with the study coordinator to fill out baseline questionnaires. 3. You will be randomly assigned to one of two groups. This means that you have a 50/50 chance (like flipping a coin) of being in either group. Neither the researchers nor you will make the choice to which group you are assigned. 4. Cognitive behavioral therapy involves meeting with a study psychologist to identify and address unhelpful automatic thoughts that may contribute to unwanted behaviors. The cognitive behavioral therapy group will meet with one-on-one with the study psychologist once per week for six weeks, using a video telemedicine platform. Each visit with the psychologist will take one hour. An attention control group is one that receives the same amount of attention as the intervention group but without the potential active ingredient. The attention control group will meet with one-on-one with a head and neck cancer clinician once per week for six weeks, using a video telemedicine platform to receive survivorship education. Each visit with will take one hour. These sessions will be video-recorded to help ensure that the interventionist delivers each intervention as intended. 5. Regardless of whether you are in the cognitive behavioral therapy or attention control group, you will meet with the study coordinator at the end of the study to complete questionnaires to measure changes compared to baseline and describe your experience in the study.

125

This qualitative case study will explore the experiences of 10-15 First-Generation Undergraduate Women (FGUW) in engineering majors at PSU that led them to apply to STEM PhD programs, and also how they overcame any barriers they encountered to then still apply. The method for data collection will include 1-2 individual semi-structured participant interviews, as well as 1-2 focus group interviews with the full participant group. During the interview process, opportunities for artifact analysis or direct observation may arise. With the permission and agreement of the participant, if these opportunities arise, I will plan to do no more than one direct observation or artifact analysis per participant.

1-2 Individual Zoom Interviews, lasting about 1 hour each. 1-2 Focus Group Interviews, lasting about 1 hour each.

$30 Amazon Gift Card

Germ Cell Tumors (GCTs) are sorted in “risk groups” that describe how much the tumor has grown in the body. The three “risk groups” are: good, intermediate, and poor. For this study, we are interested in learning more about intermediate and poor-risk GCTs, also known as “advanced” GCTs. A research study is when doctors work together to try out new ways to help people who are sick. In this study, we are trying to learn more about how to treat GCTs. Standard treatment for advanced GCTs is chemotherapy (anti-cancer drugs). Some of the drugs used may cause bad effects that show up during treatment. This study will compare the standard way to treat GCTs with the same type of treatment, but delivered over a shorter amount of time (called “accelerated” treatment). This will help us understand if the accelerated treatment is better but not more harmful than the standard treatment. We will do this by closely watching to see if the cancer grows or spreads. We do not know which treatment will be better, which is why we are doing this study.

Consent to treatment, required labs, sample collections.

The purpose of this study is to see if an online cycling group for people with aphasia is a feasible way to get people with aphasia to exercise more.

There will be 24 30-minute exercise sessions spread out over 8 weeks (3x per week). Before and after, there will be physical, mental, and cognitive assessments.

This study is being done to answer the following question: Does adding chemotherapy to immunotherapy versus immunotherapy alone help older patients with lung cancer live longer while also maintaining a good quality of life? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your lung cancer. The usual approach is defined as care most people get for lung cancer.

If the participant decide to take part in this study, they will either get pembrolizumab alone until disease progression, or chemotherapy from study-provided list of allowable choices combined with pembrolizumab for up to 2 years or until disease progression. After the participant finishes study treatment, the study doctor will continue to follow their condition for 5 years from the date of registration for survival. The participant will be followed every 3 months < 2 years from registration, and every 6 months for years 2-5.

The purpose of this study is to examine cognitive function during perimenopause and explore how these changes may be related to sex hormone levels and other psychological effects. The present study aims to address this gap by examining associations between estrogen and progesterone, as well as fluctuations in these hormone levels, in relation to cognition, measured comprehensively across self-report, behavioral measures, and neural assessments. By examining hormonal effects on cognition, the proposed study aims to inform strategies for early detection of cognitive vulnerability, promote resilience, and ultimately improve cognitive health outcomes for women across the lifespan.

Participants will be required to attend two in-person visits at our lab in Hershey, PA. At the first in-person visit, participants will complete three behavioral tasks and two computer tasks while EEG data is recorded. Participants will also complete questionnaires and give a saliva sample. Additionally, for four-weeks after this visit, participants will complete remote cognitive games and surveys via a link sent through text message and will collect saliva samples at home three times a week during this time. After four-weeks, participants will return for their second in-person visit where they will repeat the three behavioral tasks, a few questionnaires, and give another saliva sample.

$200

Comparing a brief, daily exercise program to a standard, group exercise program in treating older adults with walking difficulty. Comparación de un programa de ejercicios breves y diarios con un programa de ejercicios grupales estándar para pacientes de atención primaria con discapacidad de la movilidad.

There will be 3 in-person visits (~1 hour each) at Penn State Hershey Medical Center. You will wear a physical activity monitor 3 times. You will complete surveys at your convenience at home, online. You will meet with an exercise coach virtually via Microsoft Teams. Habrá 3 visitas presenciales (de aproximadamente 1 hora cada una) en el Centro Médico Penn State Hershey. Usará un monitor de actividad física 3 veces. Completará encuestas en línea cuando le resulte conveniente desde casa. Se reunirá virtualmente con un entrenador físico a través de Microsoft Teams. Compensación total: $110

110

This phase II/III trial tests the safety, side effects, and best dose of the drug cabozantinib in combination with standard chemotherapy, and to compare the effect of adding cabozantinib to standard chemotherapy alone in treating patients with newly diagnosed osteosarcoma. In Part 1 of the study, we will find out the highest dose of cabozantinib that can be given in combination with MAP without causing side effects that are too severe. In Part 2, subjects will either receive a combination treatment of MAP with cabozantinib or MAP alone

At the start of the study and during treatment, patients will have blood drawn to check the levels of hormones from their thyroid and proteins that are made by the pancreas. Patients will also have the protein levels checked in their urine. The protein levels in the urine will be checked. In addition, patients' blood pressure will be monitored more often than usual because they are taking cabozantinib on this study.

Amyotrophic lateral sclerosis (ALS) progresses to chronic hypercapnic (excessive carbon dioxide) respiratory failure due to chronic hypoventilation. Transcutaneous carbon dioxide (tCO2) monitoring has the potential to advance home care needs in ALS if the size, complexity, and cost of the sensor can be reduced. The aim of this study is to perform clinical validation of a novel tCO2 sensor in the setting of ALS monitoring. Simultaneous measurements of tCO2 will be performed in ALS clinic using the prototype device alongside a commercial device and standard clinical metrics of respiratory function. A group of control participants will also be recruited. Participants will be queried on technology acceptance related to commercial and experimental devices. The clinical study is designed to test 1) the concurrent validity of the prototype wearable against commercial standard and 2) user opinion about the acceptance of this technology as a device for health monitoring.

The study involves a single visit lasting 1.5 hours. You will undergo two 15-minute recordings of CO2 from sensors placed on the skin. These will occur approximately one hour apart. You will then be asked about your experiences during the recordings in a brief interview.

$20

This study will evaluate the safety and efficacy of a novel drug R07790121 compared to placebo in Crohn's disease patients. This drug is an antibody which binds to TL1A, a known important molecule in the regulation of Crohn's disease pathways. The patients who agree to participate and sign the informed consent, will receive a drug or placebo by intravenous infusion on days 0, 2, 6, and 10 of the Induction phase of treatment. During the Maintenance phase of treatment, weeks 12-52, the patients will be randomized to two doses of the drug or placebo that will be given by subcutaneous injection every four weeks. In the Open label phase of treatment, patients will receive the drug every two or every four weeks. All participants will have in-person clinic visits, will be asked to complete daily study questionnaires, provide specimens (stool, blood, urine), and have procedure done (endoscopy, ECG, blood work).

There are two screening visits to find out if subject is eligible to participate. The informed consent must be signed at the first visit, before any procedures. The subjects will be randomized for an induction treatment in two drug arms and one placebo (1:3). The Induction treatment will take 12 weeks and include five visits to the site. They may continue treatment into the Maintenance phase, weeks 12-52, There are ten visits, every four weeks. If disease returns or worsens, the subject may start the open label treatment during the maintenance. Each visit will have blood draws done, vitals check, and some have physical exam.

$75 per completed visit and $50 for travel. Total will depend on the number of visits completed

This study will look to see if radiation plus immunotherapy is better than radiation and chemotherapy.

The participant will either get chemotherapy and radiation therapy for up to 4-7 weeks, or they will get radiation therapy for 4-7 weeks plus the immunotherapy drug, pembrolizumab, given every 6 weeks for about one year (for a total of 9 doses). After the participant finishes the study treatment the study doctor will continue to follow their condition for almost 10 years, either by telephone or clinic visit, and watch them for side effects. The study doctor will monitor the participant every 3 months for 2 years, then every 6 months for 3 years and then annually for 5 years.

This study explores how the brain, eyes, and muscles work together when people use their hands to track or catch moving objects. Participants will sit and use their right hand on a tablet to follow a moving virtual ball while wearing non-invasive sensors that record brain waves (EEG), muscle activity (EMG), and eye movements. The goal is to understand how the body prepares for and responds to motion using vision and movement control. The findings may help scientists improve therapies and technologies for people with movement difficulties, such as after a stroke or brain injury.

Participants will attend one in-person session lasting approximately 2 hours. During the session, they will wear an EEG cap, EMG sensors, and an eye tracker while completing a hand-tracking task using their right hand on a tablet.

20

The proposed research is designed to provide a stronger scientific understanding of the etiology of harsh discipline and the role of parent and child individual and dyadic regulatory processes as potentially malleable mechanisms that underlie and maintain harsh discipline use. The study involves observations of parents and children in the lab and parent questionnaires over multiple time points.

Participation includes two office visits and one online survey, spread out over two years. The first visit occurs when children are 2-3 years old and then again at 4 years old. At these office visits, parents and children complete tasks and play games together, and parents fill out surveys. We will ask you and your child to wear electrode stickers that attach to the skin to measure heart rate and breathing. We will also ask to collect a small hair sample and a few saliva samples from both you and your child throughout the visit. The office visits take approximately 3 hours each. Later, when children turn 5 years old, parents receive an emailed link to a set of online surveys that can be completed at home. It typically takes about 60 minutes to complete the surveys.

$430

This study is comparing 3 arms, one in which patients will participate in Mindfulness (MAPs) Live Online. One in which patients will participate in Mindfulness (MAPs) digitally and one in which patients will participate in the control group, which is meditation only.

Screening visit will be in person. Patients will complete up to 3 hours per week of the assigned activity over a 6-week period. Participation in this study will last about 9 months.

The purpose of this study is to better understand how human teams with non-human virtual agent team members operate and function.

If you agree to be in this study, you will be fitted to sensors that will measure your neurophysiological (i.e., brain and cardiac) signals while you complete group tasks in person or in virtual reality. This interaction will be recorded and coded. You will also be asked to complete several questionnaires about your demographics, behaviors, and emotions.

$25-$40

This is Phase III study to test whether efruxifermin (EFX) helps people with a liver disease called NASH/MASH who have moderate or advanced liver fibrosis. The purpose of the study is to find out whether the study drug works and how safe it is in participants diagnosed with MASH and liver fibrosis over a long-term treatment. To answer these questions, the study drug will be compared with a placebo. The overall study duration will be up to 5 years.

Your participation in the study will last about 4 years and 11 months which includes 3 months for screening procedures (to understand if you are eligible to participate in the study), 4 years and 7 months of study drug treatment and a 30-day follow up at the end of the study. This will involve up to 36 visits to your Study Doctor. During the study, you will be asked to inject a short needle into the soft tissue under the skin (subcutaneous) in the stomach or upper thigh once a week.

Up to $3,500 over the study duration (about 4 years 11 months)

This is a study that will examine the effectiveness of using Art Therapy techniques for improvement and maintenance of self-reported coping skills and symptoms co-occurring with Autism.

The study will last approximately 18 weeks. Participants will be randomly assigned to one of three groups. The assessment only group participants will spend approximately 30 minutes completing online assessments weekly. Participants assigned to the psychoeducational group will meet weekly in person for approximately 45 minutes. Participants assigned to the full art therapy intervention group will meet weekly in person for approximately 1.5 hours. Participants will be asked to complete follow-up assessments at 1 and 3-months after the last week of the assigned group.

The purpose of this clinical research study is to learn more about the use of the investigational drug, deucrictibant, for the prevention of HAE attacks and safety in patients when used in long-term treatment. Investigational drug means that it has not yet been approved in any country for the treatment of HAE. Deucrictibant tablets are designed to block the effects of bradykinin and thus prevent HAE attacks from starting. You will receive deucrictibant tablets for 130 weeks. All participants in the study will receive one 40mg deucrictibant tablet every day. From now onwards, deucrictibant will be referred to as “study drug”. The study drug is a tablet that you will take by mouth. Every day you will have to take 1 tablet with a glass of water, at approximately the same time each day either without a meal or with a light meal. Your study doctor will provide you with detailed instructions on how and when to take the tablets.

There will be approximately 11 in person visits, and approximately 4 virtual visits. At the in person visits, blood will be drawn, EKGs performed, vital signs collected, and the study doctor will perform exams. You will need to complete a daily electronic diary, and take the study medication, an oral pill, daily.

The purpose of this clinical research study is to learn more about the use of the investigational drug, deucrictibant, for the prevention of HAE attacks. You will either receive 40mg deucrictibant or a placebo tablet every day for 24 weeks. The study drug is a tablet that you will take by mouth. Every day you will have to take 1 tablet with a glass of water, at approximately the same time each day either without a meal or with a light meal. The study consists of a Screening Phase which may last up to 10 weeks, a Treatment Phase (24 weeks), and a Follow-up Phase (up to 4 weeks). These are all described below. If you provide your consent to take part in the study and you are declared eligible to participate, your overall study participation will last approximately 10 months (38 weeks).

There will be approximately eight in person visits, blood will be drawn at six of these visits, an EKG will be performed at five of these visits, vital signs will be performed at seven of these visits, and a physical exam will be performed at five of these visits. You will be required to complete questionnaires at each visit, and complete an electronic diary.

Our overall objective is to recruit a case control study of metabolic profiles. We are hoping to learn more about metabolic profiles for people with ALS (Amyotrophic lateral sclerosis - Lou Gehrig’s Disease) and the changes that occur during disease progression. Study participants will be divided into two cohorts: ALS patients and healthy volunteers. The ALS patients will provide blood samples every 6 months, as long as possible. The healthy volunteers will only provide one blood sample upon enrollment in the study.

ALS patients will: - Review and sign informed consent - Attend a study visit lasting 15-30 minutes every 6 months - Provide blood sample every 6 months - Allow study team to access electronic medical record to collect ongoing clinical data at each study visit Healthy volunteers will: - Review and sign informed consent - Attend a single study visit lasting 15-30 minutes - Provide blood sample at enrollment - Provide height & weight - Provide information about Medcial history & medications as they pertain to diabetes and high cholesterol

The purpose of this study is to compare the usual approach to a new technique in radiotherapy delivery called stereotactic body radiotherapy (SBRT) while continuing the current treatment of immunotherapy with or without chemotherapy.

Participants will meet with the study team to discuss the study. After it has been determined that is save for them to enroll, they will need to attend all appointments. Participants will be coming to the clinic at least monthly for infusion therapy and daily for radiation. It is important that participants let the study team know how they are feeling.

The purpose of this study is to improve the treatment of children and young adults with all stages of FHWT, so that more patients are cured without relapse, and that side effects from treatment are lessened without decreasing cure rates. This study will use information on higher or lower risk features of FHWT to adjust the treatment of each subject based on their risk of relapse.

All patients will receive chemotherapy (regardless of stratum assignment) starting with 1 cycle (3 weeks) of VA (vinCRIStine, DACTINomycin) chemotherapy. Some patients will have changes in treatment based on information learned after enrollment. For all patients, at least one callback is required to be completed prior to randomization and/or prior to any change in treatment or continuation of the same treatment.

The purpose of this pilot study is to test women of color's willingness to participate in web- and laboratory-based assessments of their experiences with adversity, their cognition, indicators of poor mental and physical health, risky behaviors during pregnancy, and how they cope with stressful situations. If participants have a 3-to-5-year-old child, we will also ask if they would like their child to participate in various thinking games and biological data collection. If so, we will also assess their preschool-aged child's willingness to participate in various protocols, comprehension of protocol instructions, and ability to complete various tasks.

There will be one in-person visit to the Biobehavioral Health building to collect: -Questionnaires -Height, weight, and waist circumference -Blood pressure -Complete a challenge task -Cognitive tasks -Heart rate monitoring Participants will be asked to complete 7 days' worth of daily assessments on their phone after their in-person study visit. After completing the daily assessments, participants may be selected to participate in a follow-up interview about their experiences throughout the study. Participants will be compensated for their participation in all three portions of the study (in-person visit, daily assessments, and follow-up interview).

$88

The overarching goal of this research is to adapt, optimize, and pilot a transdiagnostic sleep and circadian intervention so that its contents and delivery are effective and sustainable for autistic adolescents

Participants will complete assessments at two time points and engage in a 6 week behavioral sleep intervention with a trained clinician.

$75.00

this trial will compare Pembrolizumab with and without MK-2870 in participants with lung cancer for disease free survival.

Participants will be required to com to all study visits, report all medications they are taking, including over the counter medications and tell the study team how they are feeling.

$50 for each completed visit

This study is being done to answer the following question: Does the use of Olaparib for one year keep your ovarian cancer from growing or returning as well as the usual approach of two years? If you decide to take part in this study, you will either get the study drug Olaparib for one or two years, with or without bevacizumab for one year, until your disease gets worse or the side effects become too severe. After you finish your treatment, your doctor and study team will watch you for side effects. They will check you every 3 months for 2 years after treatment. After that, they will check you every 6 months for 3 years. This means you will keep seeing your doctor for 5 years after treatment.

The patient will either get the study drug Olaparib for one or two years, with or without bevacizumab for one year, until their disease gets worse or the side effects become too severe. The doctor and study team will watch for side effects. They will check every 3 months for 2 years after treatment. After that, they will check every 6 months for 3 years. This means checking with the doctor for 5 years after treatment.

This study will determine how well water, an electrolyte and carbohydrate based drink, and an electrolyte only drink hydrate the body. This study will measure how long the water from these drinks stay in your body. We will look at different hormones and electrolytes in the blood and urine to determine which drink keeps fluid in your body the longest.

There will be 4 in person visits. The first is a screening visit which will take about an hour. During the next three visits we will have you drink 1 L of a beverage and we will measure your blood and urine for a few hours after you drink it to determine how well it hydrates you. There will be a blood draw at each of the 4 visits.

150

This trial will be examining the use of a drug, ifinatamab in the treatment of patients with advanced or metastatic esophageal squamous cell cancer.

After signing consent, participants will have blood tests and scans to see if they are well enough to participate. If the participate, they will need to come to the clinic to see the study team then get the experimental treatment. Participants will continue treatment until the medication no longer works, they no longer want to participate, or the study doctor feels it is not safe for them to continue.

This trial will examine which combination is better in treating Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Sorotoclax or Venatoclax.

There are three parts to this study. Screening, when you will meet the study team, sign the consent for and have tests performed to make sure that it is safe for you to participate in the study. If you join the study you will be chosen to participate in one of four arms, each with different medication to treat you disease. During the first cycle of treatment you will need to be seen by the study team between 4 and 7 times, depending upon the treatment. You will continue on the study medication until it no longer works, you have finished the trial or the doctor feels that it is no safe for your to continue ( among other reasons). The third part of the study is follow up. you will have a study visit in the clinic 30 after the last day of taking the study drug. That will be followed by after treatment follow up visits every three months until your cancer returns, if it returns. Then you will be followed every three months to see how you are doing.

Alopecia areata (AA) is an autoimmune disease that causes non-scarring hair loss that can be relapsing and chronic. It affects patients of all ages, races, and genders. Symptoms can range from patchy hair loss usually affecting the scalp, to complete scalp hair loss (alopecia universalis) or complete loss of hair on the scalp, face, and body (alopecia totalis). AA has a detrimental impact on patients' emotional wellbeing, self-esteem, social interactions, and quality of life, and psychiatric conditions such as anxiety and depression are more common in patients with AA compared to healthy controls. The purpose of this study is to find out if the study medicine, Ritlecitinib, can help with the treatment of AA.

Study participation will last approximately 57weeks. During the study, participants will attend 9 in person visits in the research office. At different timepoints the participant will have their hair examined, blood drawn, have an ECG and chest x-ray done, have photos taken of their scalp and face, answer questionnaires, and take study medication as directed by the study team.